Chartwell Investment Partners LLC reduced its stake in shares of Nightstar Therapeutics PLC (NASDAQ:NITE) by 46.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,571 shares of the company’s stock after selling 96,518 shares during the period. Chartwell Investment Partners LLC’s holdings in Nightstar Therapeutics were worth $1,464,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in NITE. Nationwide Fund Advisors acquired a new position in Nightstar Therapeutics during the 3rd quarter worth $1,196,000. Ameriprise Financial Inc. acquired a new position in Nightstar Therapeutics during the 3rd quarter worth $5,761,000. Sphera Funds Management LTD. acquired a new position in Nightstar Therapeutics during the 3rd quarter worth $1,728,000. Citadel Advisors LLC acquired a new position in Nightstar Therapeutics during the 3rd quarter worth $240,000. Finally, Alyeska Investment Group L.P. acquired a new position in Nightstar Therapeutics during the 3rd quarter worth $1,920,000. 28.63% of the stock is owned by institutional investors.
Nightstar Therapeutics PLC (NITE) opened at $10.79 on Wednesday. Nightstar Therapeutics PLC has a 52-week low of $10.05 and a 52-week high of $24.93.
Nightstar Therapeutics Profile
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.
Want to see what other hedge funds are holding NITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nightstar Therapeutics PLC (NASDAQ:NITE).
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.